Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13030804 | 0.86 | ALDH1A1 (0.42) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL421227 | 0.85 | ALDH1A1 (0.44) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL12109353 | 0.85 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL419934 | 0.85 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL4120039 | 0.83 | ALDH1A1 (0.50) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL5881010 | 0.82 | ALDH1A1 (0.41) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL535804 | 0.81 | ALDH1A1 (0.49) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL2902840 | 0.80 | LMNA (0.48) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL19543238 | 0.80 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL1607377 | 0.79 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9421275-B2 | Oligomer-calcimimetic conjugates and related compunds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | LMNA 2605/4885SMN1; SMN2 3568/4885ALDH1A1 3597/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | LMNA 700/4885SMN1; SMN2 1435/4885ALDH1A1 2770/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | LMNA 860/4885SMN1; SMN2 2365/4885ALDH1A1 3118/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | LMNA 1157/4885SMN1; SMN2 2381/4885ALDH1A1 2876/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | LMNA 2141/4885SMN1; SMN2 2077/4885ALDH1A1 2494/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | LMNA 2181/4885SMN1; SMN2 1898/4885ALDH1A1 2449/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | LMNA 811/4885SMN1; SMN2 1402/4885ALDH1A1 2572/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | LMNA 3667/4885SMN1; SMN2 1544/4885ALDH1A1 3741/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | LMNA 1408/4885SMN1; SMN2 3529/4885ALDH1A1 2393/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | LMNA 3834/4885SMN1; SMN2 4077/4885ALDH1A1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.